u/reta_and_regret

Left up, flaired Correction. The original stays with it — that is how this board works.

Left up. It reads the phase 2 paper carefully and it is honest about the intervals.

heart rate is the thing people report watching

Left up. It reads the phase 2 paper carefully and it is honest about the intervals.

Name removed. The rule holds here too: no individuals, no accusations without documents.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.

Most of the common complaints trace back to slowed gastric emptying — early fullness, reflux, nausea after a large or fatty meal. That is also why meal size and speed change the experience more than anything else.

What the glucagon arm is doing, as best anyone can say from public data.

GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.

Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.

smaller meals, earlier, is the boring advice that works

Ignored something for four days that I should have asked about on day one.

meta_analysis_mo is right that it was procedural. The procedure was not written down anywhere for you to follow.

Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.

Are you eating in the couple of hours before you sleep?

Disagree. Severe abdominal pain is not on the list of things to wait out, and this board should not be treating it as one.

Left up. It reads the phase 2 paper carefully and it is honest about the intervals.

How fast was the escalation? That is usually the variable that explains the reports.

Left up. It reads the phase 2 paper carefully and it is honest about the intervals.

Left up. It reads the phase 2 paper carefully and it is honest about the intervals.

Kept a log specifically because there is so little published. It is one person and it is not data.

if it is severe or persistent that is a clinician question, not a board question

the TRIUMPH programme is still running, so anything definitive is premature

Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

Same pattern here. It settled at a stable dose without me doing anything clever.

the glucagon component is why the metabolic story reads differently

Small fix — the shedding follows the rate of weight loss, not the compound, and it is temporary.

Are you tracking heart rate at all?

Standing reminder in every thread here: unapproved compound, research material is not for human use, nothing on this board is medical advice.

Is that the 48-week figure or an earlier readout?